Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion

Philippe Kolh, Stéphanie Rolin, Vincent Tchana-Sato, Michel Pétein, Alexandre Ghuysen, Bernard Lambermont, Julien Hanson, David Magis, Patrick Segers, Bernard Masereel, Vincent D'Orio, Jean-Michel Dogne

Research output: Contribution to journalArticlepeer-review

Abstract

To investigate whether BM-573 (N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea), an original combined thromboxane A2 synthase inhibitor and receptor antagonist, prevents reperfusion injury in acutely ischemic pigs.
Original languageEnglish
Pages (from-to)53-73
Number of pages21
JournalProstaglandins and Other Lipid Mediators
Volume79
Issue number1-2
DOIs
Publication statusPublished - Mar 2006

Keywords

  • Animals
  • Blood Pressure
  • Cardiac Output
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Female
  • Infusions, Intravenous
  • Male
  • Myocardial Reperfusion Injury
  • Receptors, Thromboxane
  • Sulfonylurea Compounds
  • Swine
  • Thromboxane-A Synthase
  • Ventricular Function, Left

Fingerprint

Dive into the research topics of 'Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion'. Together they form a unique fingerprint.

Cite this